Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26555715 | 0.84 | KIF11 (0.46) | CTSSCTSKARNSD2CYP11B2 | |
| SCHEMBL26532556 | 0.81 | CYP11B2 (0.43) | CTSKCYP11B2CYP11B1SGK1ABL1 | |
| SCHEMBL26532559 | 0.77 | GRM5 (0.42) | CTSKCYP11B2CYP11B1ABL1 | |
| SCHEMBL26627045 | 0.74 | ALOX5AP (0.37) | CTSSCTSKARCYP11B2CYP11B1 | |
| SCHEMBL26532554 | 0.73 | ALOX5AP (0.40) | KIF11ABL1 | |
| SCHEMBL7604551 | 0.73 | TRPV4 (0.56) | ARNSD2KIF11TRPV4 | |
| SCHEMBL26532558 | 0.72 | RXRA (0.38) | ABL1 | |
| SCHEMBL26627059 | 0.71 | CYP11B2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL28668535 | 0.70 | KIF11 (0.57) | ARNSD2CYP11B2PTGDR2KIF11 | |
| SCHEMBL409405 | 0.70 | TRPV4 (0.53) | CTSSCTSKARPTGDR2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230138288-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138288-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, RUVBL2, LBR | CTSS 2790/4885CTSK 4067/4885AR 1049/4885 |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, L1CAM, OPRM1 | CTSS 3803/4885CTSK 3151/4885AR 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.